EP1515728A2 - Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere - Google Patents

Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere

Info

Publication number
EP1515728A2
EP1515728A2 EP03735573A EP03735573A EP1515728A2 EP 1515728 A2 EP1515728 A2 EP 1515728A2 EP 03735573 A EP03735573 A EP 03735573A EP 03735573 A EP03735573 A EP 03735573A EP 1515728 A2 EP1515728 A2 EP 1515728A2
Authority
EP
European Patent Office
Prior art keywords
treatment
hydroxy
medicament
group
lloprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03735573A
Other languages
German (de)
English (en)
Inventor
Cornelia Norden
Nicolas Aigner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP1515728A2 publication Critical patent/EP1515728A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Definitions

  • Bone marrow edema is associated
  • the invention relates to the subject-matter set out in the patent claims, that is to say the use of orally available prostacyclin derivatives for the production of a medicament for the treatment of diseases which are associated with bone marrow edema.
  • Osteonecrosis (syn .: aseptic necrosis, avascular necrosis, ischemic necrosis) is a common disease. Pain is the main symptom. In about two thirds of the patients, this pain occurs at rest. Osteonecrosis is often described as a transient process. In the spontaneous course, there is usually a complete healing after 6 to 12 months. During this period, however, the patient is exposed to severe pain, which is often not even accessible to conventional pain therapy. The incidence rates of the progression of early osteonecrosis to the end stage with pronounced bone necrosis are not known. Osteonecrosis is responsible for more than 10% of all joint replacement surgery performed annually.
  • Knee osteoarthritis is a common disease that affects approximately 11-15% of people over 65 and is the most common cause of physical illness
  • Osteoarthritis is defined as primarily non-inflammatory joint destruction, which begins with cartilage dying in adults and later also affects the other joint structures and progresses irreversibly. The overall course is usually progressive, but changes in phases with regard to clinical acuity. In the final stage, knee replacement is necessary.
  • osteonecrosis and osteoarthritis on the hip and knee joints, but also on the shoulder, wrist and ankle. While in the treatment of osteonecrosis the surgical
  • Bone marrow relief with all its disadvantages such as inpatient stay and surgery as a means of pain relief, the treatment of osteoarthritis currently consists only of symptomatic pain treatment and is insufficiently effective. It usually includes the permanent prescription of analgesics and / or anti-inflammatory drugs, combined with physiotherapy and weight relief, and possibly the intra-articular injection of anesthetics, corticoids or "cartilage building / replacing" substances. X-ray stimulation and acupuncture are also prescribed. The treatment of arthrosis has so far been limited to symptomatic treatment.
  • the established therapies are unsatisfactory for both osteonecrosis and osteoarthritis due to the limitation to symptomatic treatment.
  • the persistence of the pain-triggering mechanisms requires long-term treatment, which is associated with additional risks and costs.
  • a causal treatment of the pain with permanent freedom from pain is therefore particularly desirable for osteoarthritis.
  • the object was therefore to find a treatment for the diseases associated with bone marrow edema, in particular osteonecrosis and osteoarthritis, which did not only relate to the symptomatic treatment, i.e. pain relief, but also restores the structural integrity of the bone, and also to provide a drug that can be taken by the patient over a long period of time without the doctor's support.
  • Prostacyclin derivatives especially the cyclodextrin clathrates of prostacyclin derivatives of the general formula I
  • R 1 is a hydrogen atom or a Ci-C-io-alkyl radical
  • W is a free or functionally modified on the hydroxy group
  • X, Y independently of one another are a -CH 2 group or an oxygen atom
  • Z is a hydrogen atom or a cyano group
  • D is a straight-chain or branched saturated -CC 5 alkylene group
  • E is a -C ⁇ C group or a direct bond
  • R 2 is a straight-chain or branched, saturated C 1 -C 7 -alkyl group
  • R 3 is a free or functionally modified hydroxyl group, and all optically active forms, racemates, diastereomers, mixtures of diastereomers, their clathrates, and if R is hydrogen, their salts with physiologically compatible bases solve the task.
  • Treatment with orally available prostacyclin derivatives, in particular with cyclodextrin clathrates of prostacyclin derivatives of formula I is a novel therapy that not only suppresses the symptoms, i.e. the pain, but also combats the cause of osteonecrosis and osteoarthritis, and for the first time also clinic can be done independently.
  • the alkyl group R 1 is straight-chain or branched alkyl groups with 1-10 carbon atoms, such as methyl, ethyl, propyl, 2-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl (tert.- Butyl), hexyl, heptyl, octyl, nonyl, decyl.
  • the alkyl group R 1 can also be substituted. Examples of substituents are fluorine, chlorine or bromine atoms, phenyl, dimethylamino, diethylamino, methoxy, ethoxy.
  • Alkyl groups with 1-4 carbon atoms are preferred as the alkyl group R 1 .
  • the alkyl group R 2 is straight-chain or branched, reference may be made, for example, to the radicals of corresponding chain length mentioned for R 1 , and has 1-7 carbon atoms, preferably 1-3 carbon atoms, particularly preferably 1-2.
  • the hydroxyl groups in R 3 and W can be functionally modified. This means esterification or etherification.
  • the ethers and / or acyl radicals thus obtained are the radicals known to the person skilled in the art.
  • Ether residues are e.g. Tetrahydropyranyl, tetrahydrofuranyl, methoxymethyl, methoxyethyl, ethoxyethyl, silyl ether such as e.g. Trimethylsilyl, dimethyl tert-butylsilyl, triphenylsilyl.
  • Acyl radicals can be, for example, acetyl, propionyl, butyryl, benzoyl.
  • X preferably has the meaning of a CH 2 group.
  • Z preferably represents a hydrogen atom.
  • alkylene group D straight-chain or branched saturated alkylene group with 1-5 carbon atoms are suitable. Examples include methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 2-methylpropylene, pentylene, 1-methylbutylene and ethylethylene. A branched alkylene group having 3 carbon atoms is preferred.
  • R 1 represents a hydrogen atom
  • the compounds of the formula I can also be present as salts of physiologically compatible bases.
  • Both inorganic and organic bases are suitable for salt formation.
  • alkali hydroxides such as sodium or
  • Potassium hydroxide alkaline earth metal hydroxides such as calcium hydroxide, ammonia, amines such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, tris (hydroxymethyl) methylamine.
  • the prostacyclin derivatives are orally available in the sense according to the invention when they can be used for oral administration after a suitable formulation.
  • prostacyclin derivatives of the general formula I formulated for oral administration: cicaprost (5 - ⁇ (E) - ( 1 S, 5S, 6S, 7R) -7-hydroxy-6 - [(3S, 4S) -3-hydroxy-4-methyl-1, 6-nonadiynyl] bicyclo [3.3.0] oct-3-ylidene ⁇ -3-oxapentanoic acid), epoprostenol ((5Z, 9, 13E, 15S) -6,9-epoxy-11,15-dihydroxy-prosta-5,13-diene-1-acid), beraprost (EP 0 084856) , Ciprostene, Taprostene, Naxaprostene, CS 570, SC-39902, FCE-22509, OP 41483
  • hoprost- ⁇ -cyclodextrin clathrate for the manufacture of a medicament for the treatment of osteonecrosis and osteoarthritis is a preferred subject of the invention.
  • lloprost is a prostacyclin analogue which is known from EP 11 591 and can be produced by the methods disclosed therein.
  • the nomenclature name for lloprost is (5 - ⁇ (1 S, 5S, 6R, 7R) -7-hydroxy-6 - [(E) - (3R, 4RS) -3-hydro) (y-4-methyl-oct- 1-en-6-ynyl] -bicyclo [3.3.0] octan-3-ylidene ⁇ -pentanoic acid).
  • lloprost- ⁇ -cyclodextrin clathrate that is known from EP 259468 and can be produced by the method disclosed therein. It is known from EP 1 016 408 that prostano ⁇ de CC chemokine production are inhibitors. According to current knowledge, the mechanisms disclosed there are not relevant for bone marrow edema.
  • Osteoarthritis is between 50 ⁇ g / day and 350 ⁇ g / day, preferably between 100 ⁇ g / day and 300 ⁇ g / day or between 150 ⁇ g / day and 350 ⁇ g / day, these amounts being able to be divided into several individual doses.
  • Healing of the bone necrosis can be achieved within a few weeks.
  • Figure 4 Case study of a patient with complete regression of an extensive bone marrow edema in the early stage of osteonecrosis.
  • the control MRI was performed 2 months after the 28 day treatment with oral lloprost was completed.
  • Figure 7 Equally pronounced increase in knee activity score according to Larson (point maximum 100) with double-blind administration of oral lloprost treatment and Tramadol ® treatment. The improvement continues over a 2-month therapy-free period. Data as mean values + SEM. p-values to compare the two
  • Treatments prove their equivalence (Hodges-Lehmann estimator and Wilcoxon test).
  • the treatment was carried out with Iloprost capsules, which were packed and labeled in accordance with the applicable GLP rules. Each capsule contained 50 ⁇ g lloprost.
  • lloprost was administered in a dose of 3x50 ⁇ g lloprost per day, which could be increased individually from day 4 up to a maximum dose of 3x100 ⁇ g lloprost per day:
  • this dosage could be achieved either by increasing the single dose (maximum: 3x100 ⁇ g lloprost per day) or by shortening the free interval (minimum: 2 h, i.e. 6x50 ⁇ g lloprost per day).
  • the dosage could be reduced at any time up to a minimum dose of 2x50 ⁇ g lloprost a day.
  • the duration of treatment was one month. Pain-relieving drugs previously administered should be discontinued before the start of the study.
  • lloprost Adverse events and side effects were recorded as safety parameters.
  • Known side effects of lloprost include symptoms such as headache, flushing, nausea, vomiting and diarrhea.
  • the study medication was administered in a dose of 3x1 capsule per day, which was administered individually from day 4 onwards
  • Enhancement of therapy success (pain relief) to a maximum Dosage of 3x2 capsules a day could be increased.
  • the dosage could be reduced at any time to a minimum dose of 2x1 capsules a day.
  • the duration of treatment was one month, followed by a treatment-free follow-up period of two months. Pain-relieving drugs previously administered should be discontinued before the start of the study.
  • Complaints such as headache, facial flushing, nausea, vomiting and diarrhea.
  • Visit 6 took place on day 56 or after 4 treatment-free weeks.
  • Visit 7 took place on day 84 or after 8 treatment-free weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de dérivés de prostacycline disponibles par voie orale pour préparer un produit pharmaceutique pour traiter des maladies qui sont associées à des oedèmes de la moelle épinière.
EP03735573A 2002-06-06 2003-06-05 Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere Withdrawn EP1515728A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10225551A DE10225551A1 (de) 2002-06-06 2002-06-06 Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
DE10225551 2002-06-06
PCT/EP2003/005990 WO2003103681A2 (fr) 2002-06-06 2003-06-05 Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere

Publications (1)

Publication Number Publication Date
EP1515728A2 true EP1515728A2 (fr) 2005-03-23

Family

ID=29594336

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03735573A Withdrawn EP1515728A2 (fr) 2002-06-06 2003-06-05 Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere

Country Status (9)

Country Link
EP (1) EP1515728A2 (fr)
JP (1) JP2005536476A (fr)
KR (1) KR20050007591A (fr)
CN (1) CN1658882A (fr)
AU (1) AU2003236715A1 (fr)
CA (1) CA2488861A1 (fr)
DE (1) DE10225551A1 (fr)
WO (1) WO2003103681A2 (fr)
ZA (1) ZA200500097B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101410119B (zh) * 2006-02-03 2012-03-07 埃科特莱茵单一股份公司 依前列醇制剂及其制备方法
TWI520740B (zh) * 2011-02-02 2016-02-11 模範健康科技私人企業有限公司 利用多硫酸化多醣之骨髓水腫（水腫）的治療
CN111278464A (zh) * 2017-08-31 2020-06-12 柏林夏瑞蒂医科大学 用于防止妥协性患者中肌肉骨骼损伤愈合不良的免疫调节

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
CA2152403C (fr) * 1992-08-07 2005-06-21 Schering Aktiengesellschaft Utilisation de derives de la prostane de formules i et ii pour l'obtention d'un medicament permettant de traiter les polyarthrites chroniques
CA2303343C (fr) * 1997-09-16 2011-01-04 Toray Industries, Inc. Inhibiteur de la production de chemokine c-c
WO2002026194A2 (fr) * 2000-09-28 2002-04-04 Non-Invasive Monitoring Systems, Inc. Addition extérieure d'impulsions à des canaux anatomiques de fluide pour libérer ou supprimer des médiateurs endothéliaux et pour déterminer l'effectivité d'une telle intervention

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03103681A2 *

Also Published As

Publication number Publication date
KR20050007591A (ko) 2005-01-19
CA2488861A1 (fr) 2003-12-18
DE10225551A1 (de) 2003-12-24
CN1658882A (zh) 2005-08-24
ZA200500097B (en) 2006-06-28
WO2003103681A2 (fr) 2003-12-18
AU2003236715A1 (en) 2003-12-22
WO2003103681A3 (fr) 2004-03-25
JP2005536476A (ja) 2005-12-02

Similar Documents

Publication Publication Date Title
DE69431729T2 (de) Bromocryptin enthaltende mittel mit beschleunigter freisetzung
DE69404675T2 (de) Pharmazeutische zusammensetzung zur intranasalen verabreichung von hydroxocobalamin
DE69423146T2 (de) Parathyroid-Hormon und Raloxifen zum Vermehren von Knochenmasse
DE69430903T2 (de) Behandlung von periodontitis mit misoprostol
DE69629184T2 (de) Verwendung von vitamin d2 oder vitamin d4-derivaten zur herstellung eines medikamentes zur behandlung des sekundären hyperparathyroidismus
DE69722401T2 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
DE69201725T2 (de) Behandlungsmethoden für osteoporose.
DE69125714T2 (de) Zusammensetzung für die behandlung des humanen prostata adenokarzinom
DE69526937T2 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
EP1265615A2 (fr) Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite
WO1998035682A1 (fr) Agent avec trois composants hormonaux pour la contraception hormonale et/ou la prophylaxie de tumeurs des glandes mammaires
DE69826132T2 (de) Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
EP0521388B1 (fr) Procédé de préparation d'une composition pharmaceutique à base d'au mains deux principes actifs différents et utilisation d'une telle composition
DE60029340T2 (de) Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
DE4328217C2 (de) Therapeutisches System zur Behandlung der Psoriasis
EP1830835A1 (fr) Utilisation d'un agoniste de recepteur vanilloide avec un glucosamine glycane ou proteoglycane pour la production d'une substance destinee a traiter les douleurs articulaires et procede d'application de ladite substance
DE3033545A1 (de) Verwendung bekannter antiallergener mittel bei der bekaempfung von pathologischen mineralresorptionszustaenden
EP0179421A2 (fr) Antigestagènes, glucocorticoides et prostaglandines pour le déclenchement de l'accouchement ou pour l'interruption de la grossesse
DE69431986T2 (de) Verwendung von granisetron zur behandlung von postoperativer übelkeit und erbrechen
EP1515728A2 (fr) Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere
EP3407899B1 (fr) Prophylaxie immunitaire pour des infections bactériennes récidivantes
DE60007179T2 (de) Pantothensäure-enthaltende arzneimittel zur behandlung von entzündlichen gelenkserkrankungen
US20050101673A1 (en) Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas
CA2219354A1 (fr) Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels
EP0484581B1 (fr) Utilisation des antagonistes du thromboxanne-A2 pour prévenir les processus dégénératifs des tissus pénils

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050103

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076381

Country of ref document: HK

17Q First examination report despatched

Effective date: 20060217

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080318

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076381

Country of ref document: HK